Literature DB >> 24029861

A narrow-band ultraviolet B course improves vitamin D balance and alters cutaneous CYP27A1 and CYP27B1 mRNA expression levels in haemodialysis patients supplemented with oral vitamin D.

Meri J Ala-Houhala1, Katja Vähävihu, Erna Snellman, Taina Hasan, Hannu Kautiainen, Piia Karisola, Yvonne Dombrowski, Jürgen Schauber, Heikki Saha, Timo Reunala.   

Abstract

BACKGROUND/AIMS: Chronic kidney disease (CKD) patients on dialysis are prone to vitamin D insufficiency despite oral vitamin D supplementation. Here, we studied whether narrow-band ultraviolet B (NB-UVB) exposures improve vitamin D balance.
METHODS: 14 haemodialysis patients and 15 healthy subjects receiving oral cholecalciferol 20 µg daily got nine NB-UVB exposures on the entire body. Serum 25-hydroxyvitamin D (25(OH)D) was measured by radioimmunoassay. Cutaneous mRNA expression levels of CYP27A1 and CYP27B1, two enzymes required for hydroxylation of vitamin D into its active metabolite, were also measured.
RESULTS: The baseline serum 25(OH)D concentration was 57.6 ± 18.2 nmol/l in the CKD patients and 74.3 ± 14.8 nmol/l in the healthy subjects. The NB-UVB course increased serum 25(OH)D by 14.0 nmol/l (95% CI 8.7-19.5) and 17.0 nmol/l (CI 13.7-20.2), respectively. At baseline the CKD patients showed significantly increased CYP27B1 levels compared to the healthy subjects.
CONCLUSIONS: A short NB-UVB course is an efficient way to improve vitamin D balance in CKD patients on dialysis who are receiving oral vitamin D supplementation. The increased cutaneous CYP27B1 levels in the CKD patients suggest that the loss of renal activity of this enzyme is at least partially compensated for by the skin.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24029861     DOI: 10.1159/000355010

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  2 in total

1.  Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk.

Authors:  Xiayu Wu; Jiaoni Cheng; Kaiyun Yang
Journal:  Int J Mol Sci       Date:  2016-09-22       Impact factor: 5.923

Review 2.  Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion.

Authors:  Sandro Giannini; Sandro Mazzaferro; Salvatore Minisola; Luca De Nicola; Maurizio Rossini; Mario Cozzolino
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.